Table 2.
Table 2A. Laboratory results and Performance of methods | |||||||||
All Groupa N = 151 |
Non previously TB treated Groupb N = 98 |
||||||||
TB N = 43 |
Non-TB N = 108 |
TB N = 36 |
Non-TB N = 62 |
||||||
Culture | Positive | 30 | 0 | 27 | 0 | ||||
Negative | 13 | 108 | 9 | 62 | |||||
SE | SP | PPV | NPV | SE | SP | PPV | NPV | ||
70% | 100% | 100 | 89 | 75% | 100% | 100 | 87 | ||
PCR dot-blot | Positive | 28 | 18 | 25 | 9 | ||||
Negative | 15 | 90 | 11 | 53 | |||||
SE | SP | PPV | NPV | SE | SP | PPV | NPV | ||
65% | 83% | 61 | 86 | 69% | 85% | 73 | 83 | ||
High PP | Positive | 31 | 15 | 26 | 4 | ||||
Negative | 12 | 93 | 10 | 58 | |||||
SE | SP | PPV | NPV | SE | SP | PPV | NPV | ||
72% | 86% | 67 | 88 | 72% | 93% | 87 | 85 | ||
Intermediate PP | Positive | 6 | 19 | 6 | 6 | ||||
Negative | 37 | 89 | 30 | 56 | |||||
SE | SP | PPV | NPV | SE | SP | PPV | NPV | ||
14% | 82% | 24 | 71 | 17% | 90% | 50 | 65 | ||
Low PP | Positive | 6 | 74 | 4 | 52 | ||||
Negative | 37 | 34 | 32 | 10 | |||||
SE | SP | PPV | NPV | SE | SP | PPV | NPV | ||
14% | 31% | 7.5 | 48 | 11% | 16% | 7.1 | 24 | ||
Table 2B. Performance of methods used in parallel | |||||||||
Performance of PCR dot-blot in parallel with High Clinical Suspicion | SE | SP | PPV | NPV | SE | SP | PPV | NPV | |
90% | 71% | 75 | 88 | 91% | 79% | 81 | 90 | ||
Performance of PCR dot-blot in parallel with Intermediate Clinical Suspicion | SE | SP | PPV | NPV | SE | SP | PPV | NPV | |
70% | 68% | 68 | 70 | 74% | 77% | 75 | 76 | ||
Performance of PCR dot-blot in parallel with Low Clinical Suspicion | SE | SP | PPV | NPV | SE | SP | PPV | NPV | |
26% | 25% | 47 | 47 | 26% | 14% | 45 | 34 |
SE: Sensitivity, SP: Specificity, PPV: Positive Predictive Value, NPV: Negative Predictive Value, PP: pretest probability (clinical suspicion).
a: All group.
b: Non previously TB treated group patients